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Background: Chlamydia trachomatis (Ct) is the most common infectious cause of blindness and bacterial sexually
transmitted infection worldwide. Ct strain-specific differences in clinical trachoma suggest that genetic polymorphisms
in Ct may contribute to the observed variability in severity of clinical disease.
Methods: Using Ct whole genome sequences obtained directly from conjunctival swabs, we studied Ct genomic
diversity and associations between Ct genetic polymorphisms with ocular localization and disease severity in a
treatment-naïve trachoma-endemic population in Guinea-Bissau, West Africa.
Results: All Ct sequences fall within the T2 ocular clade phylogenetically. This is consistent with the presence of the
characteristic deletion in trpA resulting in a truncated non-functional protein and the ocular tyrosine repeat regions
present in tarP associated with ocular tissue localization. We have identified 21 Ct non-synonymous single nucleotide
polymorphisms (SNPs) associated with ocular localization, including SNPs within pmpD (odds ratio, OR = 4.07, p* = 0.
001) and tarP (OR = 0.34, p* = 0.009). Eight synonymous SNPs associated with disease severity were found in yjfH (rlmB)
(OR = 0.13, p* = 0.037), CTA0273 (OR = 0.12, p* = 0.027), trmD (OR = 0.12, p* = 0.032), CTA0744 (OR = 0.12, p* = 0.041),
glgA (OR = 0.10, p* = 0.026), alaS (OR = 0.10, p* = 0.032), pmpE (OR = 0.08, p* = 0.001) and the intergenic region
CTA0744–CTA0745 (OR = 0.13, p* = 0.043).
Conclusions: This study demonstrates the extent of genomic diversity within a naturally circulating population of
ocular Ct and is the first to describe novel genomic associations with disease severity. These findings direct
investigation of host-pathogen interactions that may be important in ocular Ct pathogenesis and disease transmission.
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The obligate intracellular bacterium Chlamydia tracho-
matis (Ct) is the leading infectious cause of blindness
(trachoma) and the most common sexually transmitted
bacterial infection [1, 2].
Ct strains are differentiated into biovars based on patho-
biological characteristics and serovars based on serological
reactivity for the major outer membrane protein (MOMP)
encoded by ompA [3]. Serovars largely differentiate bio-
logical groups associated with trachoma (A–C), sexually
transmitted disease (D–K) and lymphogranuloma vener-
eum (LGV) (L1–L3). Despite diverse biological phenotypes,
Ct strains share near complete genomic synteny and gene
content [4], suggesting that minor genetic changes influ-
ence pathogen-host and tissue-specific infection character-
istics [5–8]. All published African ocular Ct genomes are
situated on the ocular branch within the T2 clade of non-
LGV urogenital isolates [4]. Currently there are only 31
published ocular Ct genome sequences [4, 9–12].
The pathogenesis of chlamydial infection begins with
epithelial inflammation and may progress to chronic
immunofibrogenic processes leading to blindness and in-
fertility, though many Ct infections do not result in se-
quelae [13, 14]. Strain-specific differences related to
clinical presentation have been investigated in trachoma
[8, 15, 16]. These studies examined a small number of
ocular Ct isolates from the major trachoma serotypes
and found a small subset of genes in addition to ompA
that were associated with differences in in vitro growth
rate, burst size, plaque morphology, interferon gamma
–(IFNγ) sensitivity and, most importantly, intensity of
infection and clinical disease severity in non-human pri-
mates (NHPs), suggesting that genetic polymorphisms in
Ct may contribute to the observed variability in severity
of trachoma in endemic communities [8].
The obligate intracellular development of Ct has pre-
sented significant technical barriers to basic research
into chlamydial biology. Only recently has genetic ma-
nipulation of the chlamydial plasmid been possible,
allowing in vitro transformation and modification stud-
ies, though this remains technically challenging, necessi-
tating alternative approaches [17, 18].
Whole genome sequencing (WGS) has recently been
used to identify regions of likely recombination in recent
clinical isolates, demonstrating that WGS analysis may
be an effective approach for the discovery of loci associ-
ated with clinical presentation [6]. Additionally, a num-
ber of putative virulence factors have been identified
through WGS analysis and subsequent in vitro and ani-
mal studies [5, 19–30]. However, there are currently no
published population-based studies of Ct using WGS
with corresponding detailed clinical data, making it diffi-
cult to relate genetic changes to functional relevance
and virulence factors in vivo.There is an increasing pool of Ct genomic data, largely
from archived samples following cell culture and more
recently directly from clinical samples [31]. WGS data
obtained directly from clinical samples can be preferable
to using WGS data obtained from cell-cultured Ct, since
repeated passage of Ct results in mutations that are not
observed in vivo [32–34].
Ct bacterial load is associated with disease severity, par-
ticularly conjunctival inflammation, in active (infective)
trachoma [35]. Conjunctival inflammation has previously
been shown to be a marker of severe disease and plays an
important role in the pathogenesis of scarring trachoma
[36–38]. In this study we used principal component analysis
(PCA) to reduce the dimensions of clinical grade of inflam-
mation (defined using the P score from the follicles, papillary
hypertrophy, conjunctival scarring (FPC) trachoma grading
system [39]) and Ct bacterial load to a single metric to de-
fine an in vivo conjunctival phenotype in active (infective)
trachoma. PCA is a recognized dimension reduction tech-
nique used to combine multiple correlated traits into their
uncorrelated principal components (PCs) [40–42], allowing
us to examine the relationship between Ct genotype and dis-
ease severity. These data from the trachoma-endemic region
of the Bijagós Archipelago of Guinea-Bissau currently repre-
sent the largest collection of ocular Ct sequences from a sin-
gle population and provide a unique opportunity to gain
insight into ocular Ct pathogenesis in humans.
Methods
Survey, clinical examination and sample collection
Survey, clinical examination and sample collection methods
have been described previously [43, 44]. Briefly, we con-
ducted a cross-sectional population-based survey in
trachoma-endemic communities on the Bijagós Archipelago
of Guinea-Bissau. The upper tarsal conjunctivae of each
consenting participant were examined, digital photographs
were taken, a clinical trachoma grade was assigned and two
sequential conjunctival swabs were obtained from the left
upper tarsal conjunctiva of each individual using a standard-
ized method [43]. DNA was extracted and Ct omcB (gen-
omic) copies/swab quantified from the second conjunctival
swab using droplet digital polymerase chain reaction
(ddPCR) [44, 45].
We used the modified FPC grading system for trachoma
[39]. The modified FPC system allows detailed scoring of
the conjunctiva for the presence of follicles (F score), papil-
lary hypertrophy (conjunctival inflammation) (P score) and
conjunctival scarring (C score), assigning a grade of 0–3 for
each parameter. A single validated grader conducted the
examinations, and these were verified by an expert grader
(masked to the field grades and ddPCR results) using the
digital photographs. Grader concordance was measured
using Cohen’s kappa, where a kappa > 0.9 was used as the
threshold to indicate good agreement.
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a strong association with Ct bacterial load in this and
other populations [35, 46–49]. For this study we used
PCA to combine the presence of inflammation (defined
by the P score using the FPC trachoma grading system
[39]) with Ct bacterial load (defined by tertile cut-offs il-
lustrated in Additional file 1: Figure S1) [50]. The con-
junctival disease phenotype is a dimension reduction of
these two variables, defining what we observed in the
conjunctiva at the time of sampling (Fig. 1). Dimension
reduction using PCA to define complex disease pheno-
types in genome-wide association studies (GWASs) is
well recognized, as it allows multiple traits to be in-
cluded to capture a more complex phenotype and ac-
counts for correlation between traits. This approach
therefore may reveal novel loci or pathways that would
not be evident in a single-trait GWAS, where the full ex-
tent of genetic variation cannot be captured [40].
Preparation of chlamydial DNA from cell culture
For eight specimens, WGS data were obtained following
Ct isolation in cell culture (from the first conjunctival
swab) as a preliminary exploration of Ct genomic diversity
in this population. Briefly, samples were isolated in McCoy
cell cultures by removing 100 μl eluate from the original
swab with direct inoculation onto a glass coverslip within
a bijou containing Dulbecco’s modified Eagle’s mediumFig. 1 Composite in vivo conjunctival disease severity phenotype in ocular
derived using principal component analysis (PCA) for dimension reduction
value) and C. trachomatis load (where C. trachomatis load was log transform
Additional file 1: Figure S1)). Each circle represents an individual infection (rep
load and circle colour reflects inflammatory P score (P0–P3) defined using the
grading system for trachoma [39](DMEM). The inocula were centrifuged onto cell cultures
at 1800 rpm for 30 min. Following centrifugation the cell
culture supernatant was removed and cycloheximide-
containing DMEM was added to infected cells which were
then incubated at 37 °C in 5% CO2 for 3 days. Viable Ct
elementary bodies (EBs) were observed by phase contrast
microscopy. Cells were harvested and further passaged
every 3 days until all isolates reached a multiplicity of in-
fection between 50 and 90% in 2xT25 flasks. Each isolate
was prepared and the EBs purified as described previously
[51]. DNA was extracted from the purified EBs using the
Promega Wizard Genomic Purification kit according to
the manufacturer’s protocol [52].
Pre-sequencing target enrichment
For the remaining specimens (n = 118), WGS data were
obtained directly from clinical samples. DNA baits span-
ning the length of the Ct genome were compiled by
SureDesign and synthesized by SureSelectXT (Agilent Tech-
nologies, UK). The total DNA extracted from clinical sam-
ples was quantified and carrier human genomic DNA
added to obtain a total of 3 μg input for library preparation.
DNA was sheared using a Covaris E210 acoustic focusing
unit [31]. End-repair, non-templated addition of 3′-A
adapter ligation, hybridization, enrichment PCR and all
post- reaction clean-up steps were performed according to
the SureSelectXT Illumina Paired-End Sequencing LibraryChlamydia trachomatis infection. A composite in vivo phenotype was
of two phenotypic traits: a disease severity score (using the P score
ed and cut-offs determined from the resulting density plot (see
resented on the x-axis (Index), n = 81). Circle size reflects C. trachomatis
modified FPC (follicles, papillary hypertrophy, conjunctival scarring)
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trol measures were performed between steps.
Whole genome sequencing and sequence quality filtering
DNA was sequenced at the Wellcome Trust Sanger Insti-
tute using Illumina paired-end technology (Illumina GAII
or HiSeq 2000). All 126 sequences passed standard FastQC
quality control criteria [53]. Sequences were aligned to the
most closely related reference genome, Chlamydia tracho-
matis A/HAR-13 (GenBank accession umber NC_007429.1
and plasmid GenBank accession number NC_007430.1),
using the Burrows-Wheeler Aligner (BWA) [54]. SAM-
tools/BCFtools (SAMtools v1.3.1) [55] and the Genome
Analysis Tool Kit (GATK) [56] were used to call SNPs. We
used standard GATK SNP calling algorithms, where > 10×
depth of coverage is routinely used as the threshold value
[56, 57]. This has been shown to be adequate for SNP call-
ing in this context [57–59].
Variants were selected as the intersection data set be-
tween those obtained using both SNP callers and SNPs
were further quality-filtered. SNP alleles were called using
an alternative coverage-based approach where a missing
call was assigned to a site if the total coverage was less than
20× depth or where one of the four nucleotides accounted
for at least 80% total coverage [60]. There was a clearFig. 2 Whole genome sequencing (WGS) quality filtering processes and thres
digital PCR [45]. WGS data were obtained using SureSelect target enrichment
FastQC [53] was used to assess basic WGS quality. SNP alleles were called aga
approach where a missing call was assigned to a site if the total coverage wa
for at least 80% total coverage [60]. There was a clear relationship between th
therefore, only sequences with greater than 10× mean depth of coverage ov
threshold [56, 57]. Heterozygous calls were removed and SNPs with a minor a
greater than 25% genome-wide missing data and 30% missing data per SNP
in Additional file 12: Figure S12. *n = 157 including the 71 Bijagós sequencesrelationship between the mean depth of coverage and the
proportion of missing calls, based on which we retained se-
quences with greater than 10× mean depth of coverage
over the whole genome (81 sequences retained).
Heterozygous calls were removed, and SNPs with a minor
allele frequency (MAF) of less than 25% were removed.
Samples with greater than 25% genome-wide missing data
and 30% missing data per SNP were excluded from the ana-
lysis (n = 10, 71 sequences retained). All SNP positions with
a MAF greater than 20% were identified using BCFtools
v0.1.19 (https://samtools.github.io/bcftools/). Sequences
were excluded from the final GWAS if more than 300 such
positions were found using methods described by Hadfield
et al. [61]. The quality assessment and filtering process is
shown in Fig. 2. Details of the WGS data are provided in
Additional file 2: Figure S2.
Phylogenetic reconstruction
Samples were mapped to the ocular reference strain Ct A/
HAR-13 and SNPs were called as described above. Phyloge-
nies were computed using RAxML v7.8.2 [62] from a vari-
able sites alignment using a generalized time-reversible
(GTR) + gamma model and are midpoint rooted. Recom-
bination is known to occur in Ct [4, 6] and can be problem-
atic in constructing phylogeny. We applied threehold criteria for inclusion in analyses. Ct DNA detected using droplet
[31] (or chlamydial cell culture) and Illumina paired-end sequencing.
inst reference strain Ct A/HAR-13 using an alternative coverage-based
s less than 20× depth or where one of the four nucleotides accounted
e mean depth of coverage and genome-wide proportion of missing calls;
er the whole genome were retained using the GATK Best Practices
llele frequency (MAF) of less than 25% were removed. Samples with
were excluded from the analysis. WGS sequence quality is shown in detail
in addition to 48 Rombo District sequences and 38 reference sequences
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detect regions of recombination using PhiPack [63]: the
pairwise homoplasy index (Phi), the maximum χ2 and the
neighbour similarity score (NSS) across the genome align-
ment. We also examined the confidence in the phylogenetic
tree by computing RAxML site-based likelihood scores
[62]. Phylogenetic trees were examined adjusting for re-
combination using the methods described above.
Additionally, sequence data for the tryptophan operon
(CTA0182 and CTA0184–CTA0186), tarP (CTA0498), nine
polymorphic membrane proteins (CTA0447–CTA0449,
CTA0884, CTA0949–CTA0952 and CTA0954) and ompA
(CTA0742) were extracted from the 81 ocular Ct sequences
from Guinea-Bissau retained after quality control filtering
described above, 48 ocular sequences originating from a
study conducted in Kahe village, Rombo District, Tanzania
[64] and 38 publicly available reference sequences. Phyloge-
nies were constructed as described above.
Polymorphisms, insertions and deletions (indels) and
truncations for the tryptophan operon were manually de-
termined from aligned sequences using SeaView [65]. Tyro-
sine repeat regions and actin-binding domains in tarP were
found using RADAR [66] and Pfam [67] respectively.
Pairwise diversity
A comparison was made between the two population-
based Ct sequence data sets from the Bijagós (Guinea-
Bissau) and Rombo (Tanzania) sequences whereby short
read data from the 81 Bijagós sequences and 48 Rombo
sequences were mapped against Ct A/HAR-13 using
SAMtools. Within-population pairwise nucleotide diver-
sity was calculated using the formula:
π ¼ 2 Σni¼1 Σi−1j¼1xix jπij
where n is the number of sequences, x is the frequency
of sequences i and j and πij is the number of nucleotide
differences per site between sequences i and j [68]. The
frequency of sequences was considered uniform within
the populations, and sites with missing calls were ex-
cluded on a per-sequence basis.
Genome-wide association analyses
To investigate the association between Ct polymor-
phisms with ocular localization and clinical disease se-
verity, we used permutation-based logistic regression
methods, which are powerful and well-recognized tools
in GWAS, allowing for adjustment for population struc-
ture, age and gender in the model and accounting for
multiple testing [69–72].
We used permutation analyses of 100,024 phenotypic re-
samplings, where the distribution of the p value was ap-
proximated by simulating data sets through randomization
under the null hypothesis of no association betweenphenotype and genotype. Genome-wide significance was
determined as p* ≤ 0.05, where p* was defined as the frac-
tion of re-sampled (simulated) data that returned p values
that were less than or equal to the p values observed in the
data [50]. All analyses were conducted using the R statis-
tical package v3.0.2 (the R Foundation for Statistical Com-
puting, https://www.r-project.org/) using MASS, GLM and
lsr. All R script used for these analyses is contained within
Additional file 3: Figure S3 and is released as a CC-BY open
resource (CC-BY-SA 3.0).
Ocular localization
Tissue localization is defined as the localization (or pres-
ence) of a detectable Ct infection to either the conjunc-
tival epithelium or the urogenital tract. Short read data
from the 129 clinical ocular sequences from the pairwise
diversity analysis and 38 publicly available reference se-
quences from ocular (n = 8), urogenital (n = 17) and rectal
(n = 13) sites were mapped against Ct A/HAR-13 using
SAMtools. Only polymorphic sites were retained, and
SNPs were filtered as described above. The final analysis
includes 1007 SNPs from 157 sequences, a phylogeny of
which is contained within Additional file 4: Figure S4. A
permutation-based generalized linear regression model
was used to test the association between collection site
(ocular or urogenital tissue localization) and polymorphic
sites. For each SNP the standard error for the t statistic
was estimated from the model and used to calculate the
odds ratios (ORs) and 95% confidence intervals. A χ2 test
was used to determine the association between ocular
localization-associated SNPs and both gene expression
stage and predicted localization of the encoded proteins.
The developmental cycle expression stage for each tran-
script was based on data and groupings from Belland et al.
[73]. Predicted localization of expressed proteins was de-
fined using the consensus from three predictions using
CELLO [74], PSORTb [75] and LocTree3 [76].
Clinical disease severity
A permutation-based ordinal logistic regression model
was used to test the association between the disease se-
verity score (using the in vivo conjunctival phenotype
defined previously) and polymorphic sites. The final ana-
lysis includes 129 SNPs from 71 sequences derived as
described in Fig. 2. For each SNP the standard error for
the t statistic was estimated from the model and used to
calculate the ORs and 95% confidence intervals. Individ-
uals’ age and gender were included as a covariate to the
regression analysis.
We investigated the effect of population structure on
the results of the GWAS analysis using PCA [77]. The
first three PCs captured the majority of structural vari-
ation, but including them in the model had no effect;
therefore, they were not included in the final model.
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of a polymorphism in the population was more than
90% or if there was a MAF of 3%.
Results
Conjunctival swabs collected during a cross-sectional
population-based trachoma survey on the Bijagós Archi-
pelago yielded 220 ocular Ct infections detected by Ct
plasmid-based ddPCR. Of the 220 Ct infections detected,
184 were quantifiable using Ct genome-based ddPCR.
We obtained WGS data from 126/220 samples using cell
culture (n = 8) or direct sequencing from swabs with Sure-
SelectXT target enrichment (n = 118), representing the lar-
gest cross-sectional collection of ocular Ct WGS. Eighty-
one of these sequences were subsequently included in the
phylogenetic and diversity analyses and 71 were retained in
the final genome-wide association (tissue localization (de-
rived from the anatomical site of sample collection) and
disease severity) analyses. The quality filtering process is il-
lustrated in Fig. 2 and detailed in Methods.
A total of 1034 unique SNP sites were identified within
the 126 Bijagós Ct genomes relative to the reference strain
Ct A/HAR-13. Following application of further threshold
criteria based on MAF and genome-wide missing data
thresholds, we retained only high-quality genomic data in
the final association analyses (129 SNPs from 71 se-
quences). There were no significant differences between
the 71 retained and the 55 excluded sequences with re-
spect to demographic characteristics, bacterial load, dis-
ease severity scores or geographical location (Table 1).
Clinical and demographic details of the survey participants
in whom we did not identify Ct infection have been pub-
lished previously [43]. Of the ten SNPs initially identified
within the Ct plasmid sequences, none fulfilled the quality
filtering criteria, and they were not retained for the
genome-wide association analyses.
Ocular C. trachomatis phylogeny and diversity
For the phylogeny and diversity analyses, 81 Bijagós Ct
sequences were included on the basis of the quality fil-
tering criteria described in detail in Fig. 2. SNP-based
phylogenetic trees constructed using all 1034 SNPs for
sequences above 10× coverage (n = 81), with 54 pub-
lished Ct reference genomes, are shown in Fig. 3.
The Bijagós sequences are situated within the T2 ocu-
lar monophyletic lineage with all other ocular Ct se-
quences [59] except those described by Andersson et al.
[10]. However, our population-based collection of ocular
Ct sequences has much greater diversity at whole gen-
ome resolution than previously demonstrated in African
trachoma isolates [4, 8]. We used a pairwise diversity (π)
metric to compare two populations of ocular Ct from re-
gions with similar trachoma endemicity and studies with
similar design, sample size and available epidemiologicalmetadata. These data show much greater genomic diver-
sity in the Bijagós ocular Ct sequences (π = 0.07167)
compared to the Tanzanian (Rombo) ocular Ct se-
quences (π = 0.00047).
By ompA genotyping, 73 of the Bijagós sequences are
genotype A and 8 are genotype B, supporting their classical
ocular nature (Additional file 5: Figure S5). The high reso-
lution of WGS data obtained directly from clinical samples
captures diversity that may be useful in strain classification,
particularly as we found some evidence of clustering at vil-
lage level, although the very small number of sequences per
village means that it is not possible to provide accurate esti-
mates of clustering in this study (Fig. 4).
Homoplasic SNPs and regions affected by recombin-
ation are shown in Additional file 6: Figure S6a. Removal
of these regions of recombination identified using the
pairwise homoplasy index had no effect on phylogenetic
relationships. Additionally, a site-wise log likelihood plot
demonstrated that there was no clear genomic region
where there was significant lack of confidence in the tree
construction due to recombination (Additional file 6:
Figure S6b). Whether regions containing recombination
were included or excluded, tree topology remained es-
sentially identical, indicating that branching order is not
affected by the removal of these regions.
Genome-wide analysis of C. trachomatis localization
Candidate genes thought to be involved in or indicative of
ocular localization or preference were examined to further
characterize this population of ocular Ct. Polymorphisms
and truncations in the tryptophan operon have previously
been implicated in the inability of ocular Ct to infect and
survive in the genital tract [5]. All sequences contained
mutations in trpA resulting in truncation. The majority
(80/81) were truncated at the previously characterized de-
letion at position 533 [5]. Polymorphisms in trpB and trpR
were less common (Additional file 7: Figure S7).
The variable domain structure of the translocated
actin-recruiting phosphoprotein (tarP) has also been im-
plicated in tropism [78]. Ocular strains possess more
actin-binding domains (three or four) and fewer tyrosine
repeat regions (between one and three). Urogenital
strain tarP sequences have low copy numbers of both,
and LGV strain sequences have additional tyrosine re-
peat regions. In this study, all sequences contain the ex-
pected three tyrosine repeat regions and three or four
actin-binding domains (Additional file 7: Figure S7).
The nine virulence-associated polymorphic mem-
brane proteins (Pmp) are variably related to tissue
preference, with all encoding genes except pmpA,
pmpD and pmpE clustering by tissue location [20]. In
this population all phylogenies of the six tropism-
clustering pmps show that all sequences cluster with
other ocular sequences (Additional file 8: Figure S8).
Table 1 Characteristics of ocular Chlamydia trachomatis sequences included in the disease severity association analysis
Sequence ID Sample ID Average depth
of coverage
% Missing readsa Gender Age (years) Island code Village code Ocular loadb P scorec
11152_3_1 14,344 764 0.35% M 4 002 33 202,632 1
11152_3_10 17,347 121 0.21% M 5 001 17 69,093 2
11152_3_11 4422 19 19.95% F 2 001 12 68,782 2
11152_3_12 11,231 68 2.24% M 0 003 43 64,036 1
11152_3_13 15,631 21 14.93% F 2 002 33 55,749 3
11152_3_14 6105 1664 0.05% F 1 001 14 55,202 3
11152_3_15 12,628 191 0.10% F 12 002 29 54,651 2
11152_3_16 7524 2065 0.14% M 10 002 35 54,539 2
11152_3_17 5016 61 0.44% F 1 001 15 46,510 2
11152_3_18 1485 44 1.21% F 4 002 27 45,929 1
11152_3_19 15,554 825 0.06% F 1 002 33 44,052 2
11152_3_20 6094 3070 0.00% F 3 001 14 42,917 2
11152_3_22 5082 51 0.81% M 6 001 15 42,427 1
11152_3_23 12,969 3643 1.81% F 3 002 29 41,308 3
11152_3_25 8140 246 0.36% M 13 001 20 39,816 2
11152_3_26 6083 2746 0.00% F 23 001 14 38,771 3
11152_3_27 16,621 1664 0.00% M 3 002 37 33,514 3
11152_3_28 16,852 143 0.16% M 5 002 38 31,228 2
11152_3_29 16,588 53 0.81% M 6 002 37 29,991 1
11152_3_3 4180 51 0.92% M 2 001 12 140,693 2
11152_3_30 7612 107 0.44% F 3 002 35 28,528 2
11152_3_31 6985 177 0.10% M 6 001 17 27,924 2
11152_3_32 4411 24 9.68% F 1 001 12 27,584 2
11152_3_33 4257 381 0.06% M 0 001 12 24,033 3
11152_3_34 4400 48 0.98% M 6 001 12 23,435 2
11152_3_35 15,180 571 0.35% F 7 002 33 23,254 0
11152_3_36 13,596 496 0.06% M 18 002 23 22,098 3
11152_3_37 1672 20 18.42% M 6 002 25 21,630 3
11152_3_38 5181 81 0.32% M 4 001 15 21,339 2
11152_3_39 15,532 243 0.08% F 25 002 33 21,174 2
11152_3_4 8074 150 0.13% M 4 001 18 131,175 2
11152_3_40 16,984 145 0.19% M 4 002 21 20,113 1
11152_3_41 1881 37 2.71% F 1 002 32 15,963 2
11152_3_42 10,032 101 0.16% M 2 003 42 15,706 1
11152_3_43 8492 70 2.60% M 1 004 45 15,582 2
11152_3_44 13,585 31 4.97% M 23 002 23 15,417 3
11152_3_48 7535 61 0.84% M 18 002 35 13,439 3
11152_3_5 7095 235 0.44% F 4 001 17 105,453 3
11152_3_50 6028 46 1.24% F 4 001 14 12,961 2
11152_3_52 10,021 20 16.15% F 6 003 42 11,840 1
11152_3_55 12,650 59 0.54% M 6 002 29 9001 2
11152_3_57 8965 21 16.60% M 27 003 43 7336 1
11152_3_58 5104 33 3.68% M 2 001 15 7203 2
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Table 1 Characteristics of ocular Chlamydia trachomatis sequences included in the disease severity association analysis (Continued)
Sequence ID Sample ID Average depth
of coverage
% Missing readsa Gender Age (years) Island code Village code Ocular loadb P scorec
11152_3_6 16,599 52 0.73% M 9 002 37 96,333 2
11152_3_62 7062 22 13.41% F 4 001 17 6986 3
11152_3_63 8778 17 25.47% F 11 004 46 6760 3
11152_3_66 1892 45 1.25% F 2 002 32 6374 1
11152_3_7 10,747 581 1.82% F 3 003 44 82,916 2
11152_3_70 13,189 25 8.87% F 3 002 24 4703 1
11152_3_74 15,499 24 10.49% M 5 002 33 4226 1
11152_3_76 726 417 0.06% F 3 002 26 3753 0
11152_3_77 7579 105 0.52% F 5 002 35 3468 1
11152_3_78 12,089 16 27.78% F 13 002 47 3203 2
11152_3_8 6996 38 2.03% M 3 001 17 82,614 1
11152_3_88 748 163 0.10% F 2 002 26 1636 0
11152_3_9 10,967 20 17.52% F 2 003 44 81,124 3
11152_3_92 1463 73 0.30% F 42 002 27 1273 2
13108_1_14 24,519 51 2.81% M 2 004 45 29,040 3
13108_1_15 6941 33 1.81% M 36 001 17 13,155 1
13108_1_7 25,124 27 5.27% M 4 002 22 21,750 3
13108_1_9 22,154 18 20.56% F 5 003 43 14,349 1
8422_8_49 2353 39 5.70% M 11 002 35 96,889 2
8422_8_50 2366 82 1.08% M 1 002 35 289,778 2
9471_4_86 12,980 287 1.90% M 4 002 29 85,456 1
9471_4_87 15,367 215 0.46% M 1 002 33 99,064 1
9471_4_88 15,543 192 0.11% F 23 002 33 49,125 1
9471_4_89 1870 119 0.14% M 3 002 32 158,548 3
9471_4_90 2145 111 0.11% M 15 002 32 140,297 2
9471_4_91 4158 94 0.14% M 4 001 12 63,654 1
9471_4_92 4169 85 0.13% F 3 001 12 274,835 2
9471_4_93 7590 242 0.51% F 1 002 35 128,025 3
Sequences (n = 55) were excluded from the association analysis if there was (1) < 10× coverage, (2)a > 25% missing reads genome-wide and (3) > 25% missing (N)
calls at the single nucleotide polymorphism (SNP) locus. Coverage and missing data were correlated and resulted in exclusion of the same samples irrespective of
criteria chosen. Seventy-one sequences were retained in the final disease severity analysis. bOcular C. trachomatis load = omcB (C. trachomatis genome) copies per
conjunctival swab measured using droplet digital PCR. cP score = conjunctival inflammation score (0–3) using the modified FPC (follicles, papillary hypertrophy,
conjunctival scarring) grading system for trachoma [39]
Last et al. Genome Medicine  (2018) 10:15 Page 8 of 19Permutation-based re-sampling methods, commonly
used in GWAS analyses, were used to account for multiple
comparisons [69–72]. We tested 1007 SNPs in 157 Ct se-
quences (Fig. 2) for association with ocular localization (de-
fined by anatomical site of sample collection), comparing
127 ocular, 17 urogenital and 13 LGV strains (Fig. 5a). One
hundred and five SNPs were significantly associated with
ocular localization (p* < 0.05), of which 21 were non-
synonymous (details in Table 2a and Additional file 9: Fig-
ure S9). These were within a number of genes known to be
polymorphic, genes previously identified as tropism-
associated (CTA0156, CTA0498/tarP and CTA0743/pbpB)
and virulence factors (CTA0498/tarP and CTA0884/
pmpD). Four genes contained multiple non-synonymousSNPs (CTA_0733/karG, CTA_089/5sucD, CTA_0087 and
CTA_0145/oppA_1), and ten genes contained multiple syn-
onymous SNPs. Of the genes containing multiple syn-
onymous SNPs, five contained more than three SNPs
(CTA_0739/tsf, CTA_0733/karG, CTA_0156, CTA_0154
and CTA_0153). No predicted protein localization was
over-represented in the ocular localization-related SNPs (p
= 0.6174); however, early and very-late expressed genes
were over-represented (p = 0.0197).
Markers of disease severity in ocular C. trachomatis
infection
Using permutation-based re-sampling methods, eight
SNPs were found to be significantly associated with
Fig. 3 Maximum likelihood reconstruction of whole genome phylogeny of ocular Chlamydia trachomatis sequences from the Bijagós Archipelago
(Guinea-Bissau). Maximum likelihood reconstruction of the whole genome phylogeny of 81 Ct sequences from the Bijagós Islands and 54 Ct reference
strains. Bijagós Ct sequences (n = 81) were mapped to Ct A/HAR-13 using SAMtools [55]. SNPs were called as described by Harris et al. [4]. Phylogenies
were computed with RAxML [62] from a variable sites alignment using a GTR + gamma model and are midpoint rooted. The scale bar indicates
evolutionary distance. Bijagós Ct sequences in this study are coloured black, and reference strains are coloured by tissue localization (red = Ocular,
green = Urogenital, blue = LGV). Branches are supported by > 90% of 1000 bootstrap replicates. Branches supported by 80–90% (orange) and < 80%
(brown) bootstrap replicates are indicated
Last et al. Genome Medicine  (2018) 10:15 Page 9 of 19disease severity (Fig. 5b). Seven of these are in coding re-
gions (relative to Ct A/HAR-13). Five are present at nu-
cleotide positions 465,330 (OR = 0.13, p* = 0.037),32,779 (OR = 0.12, p* = 0.032), 875,804 (OR = 0.10, p* =
0.024), 939,488 (OR = 0.10, p* = 0.026) and 1,028,728
(OR = 0.08, p* = 0.013) (where p* is the permuted p
Fig. 4 Maximum likelihood phylogenetic tree showing clustering of ocular Chlamydia trachomatis sequence types by village. RAxML maximum
likelihood phylogenetic reconstruction including all ocular Ct sequences retained in the final disease severity association analysis after quality
filtering (n = 71). Ocular Ct sequences are labelled by village (villages numbered and coloured), midpoint-rooted and mapped to reference Ct A/
HAR-13. Branches are supported by > 90% of 1000 bootstrap replicates. Branches supported by 80–90% (orange) and < 80% (brown) bootstrap
replicates are indicated
Last et al. Genome Medicine  (2018) 10:15 Page 10 of 19value with a genome-wide threshold of 0.05) represent-
ing synonymous codon changes within the genes yjfH,
trmD, alaS, glgA and pmpE respectively. Three further
genome-wide significant synonymous SNPs were
present at positions 827,184 (OR = 0.3, p* = 0.041)
within the predicted coding sequence (CDS)
CTA0744, 285,610 (OR = 0.12, p* = 0.027) within
CTA0273 and 787,841 (OR = 0.13, p* = 0.043) in the
intergenic region between loci CTA0744–CTA0745
(Table 2b and Additional file 10: Figure S10).
Discussion
This collection of clinical ocular Ct WGS from a single
trachoma-endemic population to be characterized hasenabled us to describe the population diversity of naturally
occurring Ct in a treatment-naïve population. We used de-
tailed clinical grading combined with microbial quantitation
to perform a GWAS and investigated associations between
Ct polymorphisms with ocular localization and disease se-
verity in trachoma.
Unlike the recently published Australian Ct sequences
[10], all Bijagós sequences clustered as expected within the
T2 ocular clade derived from a urogenital ancestor [59, 61],
each with loci typically associated with ocular tissue
localization (trpA and tarP). Although the Bijagós sequences
conform to the classical ocular genotype, the phylogenetic
data show greater than expected diversity compared to his-
torical reference strains of ocular Ct [4] and a population of
Fig. 5 Single nucleotide polymorphisms on the Chlamydia trachomatis genome associated with (a) ocular localization and (b) disease severity at
genome-wide significance. a Ocular localization-associated SNPs across the C. trachomatis genome. There were 1007 SNPs identified in coding
and non-coding regions and included in permutation-based linear regression models in the Ct genome-wide association analysis. The threshold
for genome-wide significance is indicated by the dashed line (p* < 0.05). The y-axis shows the –log10 p value. A –log10 p value of 1.3 is equivalent
to a permuted p value of 0.05 (p* < 0.05). Synonymous (black) and non-synonymous SNPs (red) are indicated. Regions informative for
ocular localization and genes of interest are labelled in blue. b Disease severity-associated SNPs across the Ct genome. From 129 SNPs
identified in coding and non-coding regions, SNPs associated with the disease severity phenotype at genome-wide significance are
identified using permutation-based ordinal logistic regression models adjusting for age in the Ct genome-wide association analysis.
The threshold for genome-wide significance is indicated by the dashed line (p* < 0.05). The y-axis shows the –log10 p value. A log10 p value of 1.3 is
equivalent to a permuted p value of 0.05 (p* < 0.05). Genes significantly associated with disease severity are labelled in blue
Last et al. Genome Medicine  (2018) 10:15 Page 11 of 19clinical ocular Ct sequences obtained from cultured clinical
conjunctival swab specimens collected from another African
trachoma-endemic population [64] (Additional file 4: Figure
S4). Our use of direct WGS from clinical samples reveals
the natural diversity of a population-based collection ofendemic treatment-naïve ocular Ct infections. This diversity
may indicate genome-wide selection for advantageous mu-
tations as demonstrated in other pathogens [79] or simply
the naturally diverse circulation of endemic treatment-naïve
ocular Ct.
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Last et al. Genome Medicine  (2018) 10:15 Page 15 of 19The apparent village-level clustering provides new evi-
dence that WGS has the necessary molecular resolution
to fully investigate Ct transmission. Although the number
of sequences from each village was very small, overall Ct
genomic diversity supports our hypothesis of ongoing or
recent transmission, since diversity requires mutation, re-
combination and gene flow. The data from this study
demonstrate such mutation and indicate that WGS data
may be useful in defining transmission networks and de-
veloping transmission maps, which have not been ad-
equately defined using alternative Ct genotyping systems.
Whole genome mapping has previously been shown to be
a useful tool in the analysis of outbreaks and bacterial
pathogen transmission [80, 81] and thus has multiple po-
tential applications in epidemiological analysis and trans-
mission studies. However, greater numbers of sequences
per village are required to validate this finding.
Such diversity is likely to be representative of recom-
bination present in Ct [82]. Genome-wide recombination
was common and widespread within these sequences.
Extensive recombination has been noted in previous
studies and is thought to be a source of diversification
with possible interstrain recombination [4, 82]. Recom-
bination may represent fixation of recombination in re-
gions that are under diversifying selection pressure [4].
Recently, a handful of bacterial GWASs have provided
insight into the genetic basis of bacterial host preference,
antibiotic resistance and virulence [83–88]. Until now,
most inferences regarding disease-modifying virulence
factors in chlamydial infection have been derived from a
limited number of comparative genomic studies where
only a few virulence factors were associated with disease
severity. Chlamydial genomic association data have pre-
viously been used to highlight genes potentially involved
in pathoadaptation [10, 89] and tissue localization [90].
In the current GWAS we found 21 genome-wide sig-
nificant non-synonymous SNPs associated with ocular
localization and eight genome-wide significant synonym-
ous SNPs associated with disease severity.
Confidence that new SNPs identified in the ocular
localization GWAS are candidate markers of pathoadapta-
tion is supported by the observation that half of the SNPs
identified have previously been described as polymorphic or
recombinant within Ct and the ocular serovars [8, 91–93].
In support of the hypothesis that early events in infec-
tion and intracellular growth are crucial events in Ct
survival and pathogenicity, we identified SNPs within
genes that are expressed from the beginning of the chla-
mydial developmental cycle including CTA0156 (encod-
ing early endosomal antigen 1 (EEA1) [73]), CTA0498
(encoding translocated actin-recruiting phosphoprotein
(tarP) [94]) and CTA0884 (encoding polymorphic mem-
brane protein D (PmpD) [95]), which have identified
roles in entry to and initial interactions with host cells.Two of the four genes containing multiple non-
synonymous SNPs (karG and sucD) are involved in
ATP metabolism and, more generally, chlamydial
metabolism. Two of the genes with multiple syn-
onymous mutations (ruvB and CTA_0284) are also
involved in metabolism. Growth rates are known to
vary significantly between biovars. The developmen-
tal cycle in ocular serovars is substantially longer
than that in genital serovars [96]. These genes and
the identified SNPs may therefore be important in
the differential growth and development of Ct sero-
vars. This is supported by the downregulation of
sucD expression during in vitro persistence. Slower
growth in ocular strains occurs primarily in the
entry and early stages of differentiation, which may
also indicate the role of previously described genes
involved in entry into cells.
The eight disease severity-associated SNPs are within
less well-characterized genes. Apart from pmpE, the
remaining genes identified in this study have been
shown to be relatively conserved [90]. This suggests
that these SNPs may be important in ocular Ct patho-
genesis, rather than in longer term chlamydial evolu-
tion. Three of these genes are putative Ct virulence
factors, with functions in nutrient acquisition (glgA [24,
28, 97]), host-cell adhesion (pmpE [98]) and response
to IFNγ-induced stress (trmD [73]). Homologues of
alaS [99, 100] and CTA0273 [101, 102] are known viru-
lence factors in related Gram-negative bacteria, sug-
gesting that these genes are potentially important in Ct
pathogenesis.
Transcriptome analysis of chlamydial growth
in vitro has shown that there is highly upregulated
gene expression of trmD (encoding a transfer RNA
(tRNA) methyltransferase) associated with growth in
the presence of IFNγ, thought to be important in the
maintenance of chlamydial infection [73]. yjfH
(renamed rlmB) is phylogenetically related to the
TrmD family and encodes the protein RlmB, which is
important for the synthesis and assembly of the com-
ponents of the ribosome [103]. In Escherichia coli,
Haemophilus influenzae and Mycoplasma genitalium,
RlmB catalyses the methylation of guanosine 2251 in
23S ribosomal RNA (rRNA), which is of importance
in peptidyl tRNA recognition but is not essential for
bacterial growth [103, 104]. alaS encodes a tRNA lig-
ase of the class II aminoacyl tRNA synthetase family
involved in cytoplasmic protein biosynthesis. It is not
known to have virulence associations in chlamydial
infection, but has been described as a component of
a virulence operon in Haemophilus ducreyi [99] and
H. influenzae [100]. The CDS CTA0273 encodes a
predicted inner membrane protein translocase compo-
nent of the autotransporter YidC, an inner membrane
Last et al. Genome Medicine  (2018) 10:15 Page 16 of 19insertase important in virulence in E. coli [101] and
Streptococcus mutans [102]. Our study suggests that
these loci may be important in disease severity and
host-pathogen interactions in chlamydial infection. A
summary of available literature for these key ocular
localization and disease severity-associated SNPs is
tabulated in Additional file 11: Figure S11. We cannot
speculate further on the effect of these polymor-
phisms on expression. It is possible that the syn-
onymous disease severity-associated SNPs are markers
in linkage for disease-causing alleles that were not in-
cluded in the final GWAS analysis. For both analyses,
further mechanistic studies are required to establish
causality and validity and to fully understand the na-
ture of the associations presented.
Though we were intrinsically limited to those cases
where infection was detectable and from which we
were able to obtain Ct WGS data, our population-
based treatment-naïve sample attempts to provide a
representative picture of what is observed in ocular
Ct infection. We acknowledge that there may be Ct
genotypes that are cleared by the immune system
such that we do not capture them in a cross-sectional
study. We are limited to the small sample size in this
study, but attempt to address the issues of statistical
power and multiple testing by using a bi-dimensional
conjunctival phenotype and permutation-based multi-
variable regression analysis. To date, many published
microbial GWASs have sample sizes under 500 [105],
including several key studies examining virulence [84]
and drug resistance [85] in Staphylococcus aureus
with sample sizes of 75 and 90 respectively.
Conclusions
The potential of bacterial GWASs has only recently
been realized, and despite the limitations with sample
size, their use to study Ct in this way is particularly
important, since in vitro models are intrinsically diffi-
cult to develop, and it has not been possible to study
urogenital Ct in the same way due to the lack of a
clearly defined in vivo disease phenotype. The gen-
omic markers identified in this study provide import-
ant direction for validation through in vitro functional
studies and a unique opportunity to understand host-
pathogen interactions likely to be important in Ct
pathogenesis in humans. The greater than expected di-
versity within this population of naturally circulating
ocular Ct and the clustering at village level demon-
strate the potential utility of WGS in epidemiological
and clinical studies. This will enable us to understand
transmission in both ocular and urogenital Ct infec-
tion and will have significant public health implica-
tions in preventing and eliminating chlamydial disease
in humans.Additional files
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